

Resource Summary Report

Generated by [kravitz2](#) on Aug 11, 2026

Brilliant Violet 711(TM) anti-mouse/human CD11b

RRID:AB_11218791

Type: Antibody

Proper Citation

BioLegend Cat# 101241, RRID:AB_11218791

Antibody Information

URL: http://antibodyregistry.org/AB_11218791

Proper Citation: BioLegend Cat# 101241, RRID:AB_11218791

Target Antigen: CD11b

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 711(TM) anti-mouse/human CD11b

Description: This monoclonal targets CD11b

Target Organism: cynomolgus, mouse, rhesus, human

Clone ID: Clone M1/70

Antibody ID: AB_11218791

Vendor: BioLegend

Catalog Number: 101241

Alternative Catalog Numbers: 101242

Record Creation Time: 20250819T223029+0000

Record Last Update: 20250820T022510+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 711(TM) anti-mouse/human CD11b.

No alerts have been found for Brilliant Violet 711(TM) anti-mouse/human CD11b.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 34 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Fujino T, et al. (2026) Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias. Cancer discovery.

Allen NC, et al. (2026) NF- κ B-activated fibroblasts orchestrate inflammaging and emergence of pro-inflammatory granzyme K⁺ T cells. Immunity, 59(6), 1561.

Xu Y, et al. (2026) A dysregulated hepcidin-iron axis impairs antiviral immunity and induces lethal liver pathology in neonates. Immunity, 59(1), 79.

Foidart P, et al. (2026) Whole-genome doubling drives immune evasion by silencing antigen presentation. Cancer cell, 44(7), 1418.

Lee D, et al. (2026) Interleukin-4-producing type 2 innate lymphoid cells in the lymph node promote proallergic Tfh13 cell differentiation. Immunity, 59(7), 1860.

Lubrano S, et al. (2025) FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. Cancer cell, 43(3), 428.

Hao Y, et al. (2025) Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition. Cancer immunology research, 13(2), 185.

Nyberg WA, et al. (2025) In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313. Immunity, 58(2), 499.

Rokan A, et al. (2025) Evolution of a melanoma that escapes allogeneic rejection. Cell reports, 44(9), 116288.

Murali SV, et al. (2025) CX3CR1 Fate-Mapping In Vivo Distinguishes Cochlear Resident and Recruited Macrophages After Acoustic Trauma. bioRxiv : the preprint server for biology.

Garrett A, et al. (2025) Vagal blockade of the brain-liver axis deters cancer-associated cachexia. Cell, 188(21), 6044.

Cook DR, et al. (2025) Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM. *Frontiers in immunology*, 16, 1579925.

Young RE, et al. (2025) Disruption of E-cadherin in the airway led to dysplastic stressed cells and asthma-like phenotypes. *Developmental cell*.

Blanchard L, et al. (2025) Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade. *Cell reports. Medicine*, 6(6), 102141.

Bessell E, et al. (2024) Stromal cell and B cell dialogue potentiates IL-33-enriched lymphoid niches to support eosinophil recruitment and function during type 2 immunity. *Cell reports*, 43(8), 114620.

Rashidi A, et al. (2024) Myeloid cell-derived creatine in the hypoxic niche promotes glioblastoma growth. *Cell metabolism*, 36(1), 62.

Li Y, et al. (2023) Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1. *Cell reports. Medicine*, 4(11), 101282.

Ahn M, et al. (2023) Bat ASC2 suppresses inflammasomes and ameliorates inflammatory diseases. *Cell*, 186(10), 2144.

Arang N, et al. (2023) High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. *Cell reports. Medicine*, 4(11), 101244.

Merana GR, et al. (2022) Intestinal inflammation alters the antigen-specific immune response to a skin commensal. *Cell reports*, 39(9), 110891.